28 results about "Pneumococcal infections" patented technology

The invention relates to the technical field of biology, in particular to a polyvalent pneumococcal polysaccharide-protein conjugate composition for preventing pneumococcal infection and VZV infection as well as a preparation method and application of the polyvalent pneumococcal polysaccharide-protein conjugate composition. According to the composition containing the multivalent pneumococcal polysaccharide-protein conjugate, an adopted carrier protein is a VZV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the VZV recombinant protein through a covalent bond; the VZV recombinant protein is selected from gE protein, and the amino acid sequence of the VZV recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. Aiming at the main epidemic condition of specific serotype pneumococcus in China, serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F are creatively selected, so that the composition containing the multivalent pneumococcus polysaccharide-protein conjugate, which is designed aiming at the epidemic condition of the specific serotype pneumococcus in China, is developed.

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

This invention relates to the field of biotechnology, specifically to a composition containing a multivalent pneumococcal polysaccharide-protein conjugate for the prevention of pneumococcal infection and VZV infection, its preparation method, and its application. The composition of this invention, comprising a multivalent pneumococcal polysaccharide-protein conjugate, uses an immunogenic VZV recombinant protein as the carrier protein; the pneumococcal polysaccharide is covalently linked to the VZV recombinant protein; the VZV recombinant protein is selected from gE protein, and its amino acid sequence is shown in SEQ ID NO: 3 or SEQ ID NO: 4. This invention addresses the prevalence of serotypes of pneumococcus unique to my country by creatively selecting serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. This results in a composition containing polyvalent pneumococcal polysaccharide-protein conjugates designed specifically for the prevalence of these serotypes in my country.

Technologies for the prevention and / or treatment of pneumococcal infections.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. The immunogenic compositions of the invention typically comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. The present invention also relates to the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection using said novel immunogenic compositions.

This invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular glycoantigens (glycoconjugates) and their uses. The immunogenic compositions of this invention will generally comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. This invention also relates to the use of said novel immunogenic compositions for the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection.

Provided are a pneumococcal conjugate combined vaccine and a preparation method therefor. The combination comprises 26 different pneumococcal polysaccharide-protein conjugates, and the pneumococcal polysaccharide comprises a total of 26 serotypes, i.e., 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 24F, 33F and 35B. The carrier protein used by the conjugate is tetanus toxoid (TT). The polysaccharide is covalently linked to the TT by means of a cyano activation method so as to prepare a polysaccharide-protein conjugate stock solution, and the polysaccharide-protein conjugate stock solution is then adsorbed by an aluminum adjuvant in an appropriate proportion so as to obtain the pneumococcal conjugate vaccine. The pneumococcal polysaccharide used therein requires no degradation reaction, effectively protecting the antigenicity of the polysaccharide. Three consecutive batches of production of the conjugate stock solution and vaccine are performed, and the yield and each verification index of the conjugate are stable. The results of non-clinical safety evaluation research show that the vaccine has good safety and immunogenicity. The prepared pneumococcal conjugate vaccine is used for immunoprophylaxis of pneumococcal infection of relevant serotypes.

A pneumococcal polysaccharide-RSV recombinant protein conjugate vaccine for preventing pneumococcal infection and RSV infection and a preparation method therefor. The pneumococcal polysaccharide-RSV recombinant protein conjugate vaccine has an RSV recombinant protein that is an RSV Pre-F recombinant protein with enhanced stability due to amino acid mutation modification. The RSV recombinant protein has immunogenicity and is used as a carrier protein of pneumococcal polysaccharide. In the pneumococcal polysaccharide-RSV recombinant protein conjugate vaccine, by means of the amino acid mutation modification on an RSV PreF protein carrier, the protein can still maintain the structural stability and an antigen cluster function in different environments, including high temperature, acidity, and high osmotic pressure. The conjugate vaccine has dual immunogenicity and can simultaneously effectively prevent diseases caused by streptococcus pneumoniae and RSV.

FIELD: biotechnology.SUBSTANCE: composition for protecting or treating a human susceptible to pneumococcal infection is described, comprising: (i) at least 21 different glycoconjugates; (ii) a succinate buffer having a pH in the range of 5.0 to 7.5; (iii) sodium chloride; (iv) sodium phosphate; (iv) a surfactant; and (v) an adjuvant.EFFECT: vaccine formulation that facilitates resuspension of the vaccine for administration.71 cl, 7 dwg, 3 tbl, 6 ex

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

The present invention relates to compositions and methods for the treatment of infection caused by Streptococcus pneumonia. In particular, the invention provides human hyperimmune globulin and compositions thereof for preventing or treating pneumococcal infection. The invention provides methods of producing hyperimmune globulin containing high titers of opsonophagocytic anti-pneumococcal antibodies, compositions containing same, and methods of using the compositions for the prevention and treatment of pneumococcal infection. The invention further provides methods of preventing or treating pneumococcal infection (e.g., upper respiratory infections (e.g., bronchitis, otitis, sinusitis, etc.)) in immunocompromised subjects via administration of hyperimmune globulin compositions of the invention (e.g., containing a high titer of opsonophagocytic anti-pneumococcal antibodies) to immunocompromised subjects.

The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and / or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

The invention relates to vaccination of human subjects, in particular elderly, against bacterial infections, wherein the bacterial infection is not pneumococcal, and COVID-19 infections.

Technologies for the prevention and / or treatment of pneumococcal infections.

Technologies for the prevention and / or treatment of pneumococcal infections.

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

The present invention relates to the field of biotechnology, and particularly relates to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus (RSV) infection, and a preparation method and application thereof. In the multivalent pneumococcal polysaccharide-protein conjugate vaccine of the present invention, the carrier protein is an RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is covalently linked to the RSV recombinant protein; the RSV recombinant protein is selected from the Pre-F protein, and its amino acid sequence is as shown in SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine of the present invention is an innovative vaccine, and can be used to simultaneously prevent two common diseases, namely pneumonia and RSV infection, by using one vaccine product, greatly reducing the number of vaccine inoculations. By mutating and modifying the carrier protein in the conjugate vaccine, the present invention can enable the carrier protein to maintain structural stability and antigenic cluster function under different environments.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

The present invention relates to a novel immunogenic composition containing a conjugated Streptococcus pneumoniae capsular sugar antigen (sugar conjugate), a kit containing the immunogenic composition, and the use of the same. The immunogenic composition of the present invention typically contains at least one sugar conjugate derived from a Streptococcus pneumoniae serotype not found in PREVNAR®, SYNFLORIX®, and / or PREVNAR13®. The present invention also relates to the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection using the novel immunogenic composition.

The invention relates to an isolated peptide five to eleven amino acids in length of the sequence B1X6X7X8X9B2, wherein B1 is selected from - X1X2X3TX5, - X2X3TX5, - X3TX5, - TX5, - X5 and - no amino acid, with X1 being V or A, X2 being N or Q, X3 being A or T, and X5 being D, E or A. - X6 is D, E and A; - X7 is D, E or A; - X8 is R, L or A; - X9 is W or A; and B2 is selected from f: - X10A, - X10 and - no amino acid with X10 being N or A, and wherein at most two of X5, X6, X7, X9 and X10 are A; and its use in treatment a bacterial infection. A particular advantage of the peptides disclosed herein is their ability to revert drug resistant strains, particularly pneumococcal strains, to susceptibility to antibacterial drugs.

FIELD: occupational medicine.SUBSTANCE: used to diagnose immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in the solid phase. Samples of venous blood and smears from the mucous membrane of the pharynx are taken. In the presence of Streptococcus pneumoniae DNA in scrapings from the mucous membrane of the pharynx and with the level of immunoglobulin M in the blood serum≤ 1.7 g / l is used to diagnose immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in the solid phase.EFFECT: method provides the possibility of selecting immunocompromised workers exposed to industrial mixed aerosols for priority vaccination against pneumococcal infection at the stage of periodic medical examination, by determining the level of immunoglobulin M in the blood serum and Streptococcus pneumoniae DNA in swabs from the mucous membrane of the pharynx.1 cl, 1 tbl, 1 ex

Technologies for the prevention and / or treatment of pneumococcal infections.

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

The present invention relates to novel immunogenic compositions comprising conjugated capsular saccharide antigens of Streptococcus pneumoniae (glycoconjugates) and uses thereof. The immunogenic compositions of the invention will generally comprise at least one saccharide conjugate from a serotype of Streptococcus pneumoniae that is not found in Prevnar, Synflorix and / or Prevnar 13. The invention also relates to the use of the novel immunogenic compositions for vaccinating human subjects, particularly infants and the elderly, against pneumococcal infection.